Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR.

Br J Haematol. 2019 May 28. doi: 10.1111/bjh.15997. [Epub ahead of print]

PMID:
31135975
2.

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN.

Leuk Res. 2019 Jun;81:1-9. doi: 10.1016/j.leukres.2019.03.009. Epub 2019 Apr 4.

PMID:
30978434
3.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

4.

Epstein-Barr Virus-Positive Mucocutaneous Ulcer in an Immunosuppressed Patient.

Hujoel IA, Rubio-Tapia A, Dao LN, Porrata LF, Kane SV.

ACG Case Rep J. 2018 Apr 25;5:e32. doi: 10.14309/crj.2018.32. eCollection 2018.

5.

Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation.

Porrata LF.

J Clin Apher. 2018 Jun;33(3):324-330. doi: 10.1002/jca.21611. Epub 2017 Dec 12. Review.

PMID:
29232011
6.

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.

Kansagra A, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN, Porrata LF.

Bone Marrow Transplant. 2018 Feb;53(2):146-154. doi: 10.1038/bmt.2017.225. Epub 2017 Oct 16.

PMID:
29035394
7.

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.

Failing JJ, Yan Y, Porrata LF, Markovic SN.

Melanoma Res. 2017 Dec;27(6):596-600. doi: 10.1097/CMR.0000000000000404.

PMID:
29016387
8.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

PMID:
28961306
9.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE.

Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4.

PMID:
28869617
10.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE.

Br J Haematol. 2017 Aug;178(3):427-433. doi: 10.1111/bjh.14688. Epub 2017 May 3.

PMID:
28466487
11.

Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma.

Binder M, O'Byrne MM, Maurer MJ, Ansell S, Feldman AL, Cerhan J, Novak A, Porrata LF, Markovic S, Link BK, Witzig TE.

Am J Hematol. 2017 Aug;92(8):752-758. doi: 10.1002/ajh.24758. Epub 2017 Jun 1.

12.

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients.

Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2017 Mar 31;7(3):e550. doi: 10.1038/bcj.2017.30.

13.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

14.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB.

JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. Review.

15.

Autologous Graft-versus-Tumor Effect: Reality or Fiction?

Porrata LF.

Adv Hematol. 2016;2016:5385972. doi: 10.1155/2016/5385972. Epub 2016 Aug 22. Review.

16.

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S, McGuirk JP, Abhyankar S.

Bone Marrow Transplant. 2016 Sep;51(9):1268-70. doi: 10.1038/bmt.2016.111. Epub 2016 Apr 25. No abstract available.

PMID:
27111048
17.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS.

Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2.

18.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.

Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nevala W, Markovic SN.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1017-1023. doi: 10.1016/j.bbmt.2016.01.024. Epub 2016 Jan 27.

19.

Adaptive cancer treatment: why I put my money on immunotherapy.

Porrata LF.

Lancet Haematol. 2015 Oct;2(10):e402-3. doi: 10.1016/S2352-3026(15)00189-1. Epub 2015 Oct 1. No abstract available.

PMID:
26686038
20.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223. Epub 2015 Nov 26.

21.

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, Zhang Z, Dietz AB, Porrata LF, Novak AJ, Liang AB, Yang ZZ, Ansell SM.

Blood Cancer J. 2015 Jul 31;5:e328. doi: 10.1038/bcj.2015.56.

22.

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.

J Hematol Oncol. 2015 Jul 3;8:80. doi: 10.1186/s13045-015-0178-5.

23.

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M.

Blood. 2015 Jul 16;126(3):328-35. doi: 10.1182/blood-2015-02-629543. Epub 2015 Apr 28.

24.

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.

J Blood Med. 2015 Feb 2;6:45-53. doi: 10.2147/JBM.S75784. eCollection 2015.

25.

Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD.

Am J Hematol. 2015 Apr;90(4):334-8. doi: 10.1002/ajh.23939. Epub 2015 Jan 30.

26.

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK.

J Clin Oncol. 2014 Nov 1;32(31):3506-12. doi: 10.1200/JCO.2014.55.7561. Epub 2014 Sep 29.

27.

Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.

Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, Lin Y, Thompson C, Gupta M, Katzmann JA, Cerhan JR.

Am J Hematol. 2014 Dec;89(12):1116-20. doi: 10.1002/ajh.23839. Epub 2014 Sep 26.

28.

Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant.

Thoma MD, Glejf J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND, Patnaik MM, Litzow MR, Hogan WJ, Newell LF, Chandran R, Porrata LF, Holtan SG.

BMC Hematol. 2014 Sep 1;14(1):14. doi: 10.1186/2052-1839-14-14. eCollection 2014.

29.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.

PMID:
25135992
30.

Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1804-12. doi: 10.1016/j.bbmt.2014.07.012. Epub 2014 Jul 17.

31.

Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.

Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.

Leuk Lymphoma. 2014 Dec;55(12):2728-38. doi: 10.3109/10428194.2014.893313. Epub 2014 Mar 19.

PMID:
24547705
32.

Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.

Burnette BL, Jentoft MA, Porrata LF, Boyce TG, Witzig TE.

J Clin Oncol. 2014 Mar 1;32(7):e14-7. doi: 10.1200/JCO.2012.47.6994. Epub 2014 Jan 6. No abstract available.

33.

Absolute monocyte count at diagnosis and survival in mantle cell lymphoma.

Porrata LF, Ristow K, Markovic SN.

Br J Haematol. 2013 Nov;163(4):545-7. doi: 10.1111/bjh.12531. Epub 2013 Aug 21. No abstract available.

PMID:
23961917
34.

The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma.

Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN.

Am J Clin Oncol. 2015 Jun;38(3):252-8. doi: 10.1097/COC.0b013e31829b5605.

35.

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, Kumar SK.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1233-7. doi: 10.1016/j.bbmt.2013.05.019. Epub 2013 Jun 6.

36.

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.

Bone Marrow Res. 2013;2013:658371. doi: 10.1155/2013/658371. Epub 2013 Apr 28.

37.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE.

Ann Oncol. 2013 Sep;24(9):2439-43. doi: 10.1093/annonc/mdt188. Epub 2013 May 22.

38.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ.

Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.

39.

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.

Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA.

Bone Marrow Transplant. 2013 Oct;48(10):1302-7. doi: 10.1038/bmt.2013.53. Epub 2013 Apr 22. Review.

PMID:
23604010
40.

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma.

Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.

Blood Cancer J. 2013 Apr 19;3:e110. doi: 10.1038/bcj.2013.8.

41.

A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.

Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR.

Leuk Lymphoma. 2013 Aug;54(8):1713-8. doi: 10.3109/10428194.2012.753444. Epub 2012 Dec 31.

PMID:
23189958
42.

Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.

DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, Litzow MR, Hogan WJ, Porrata LF, Holtan SG.

Bone Marrow Transplant. 2013 May;48(5):708-14. doi: 10.1038/bmt.2012.211. Epub 2012 Oct 29.

PMID:
23103674
43.

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S.

Biol Blood Marrow Transplant. 2013 Jan;19(1):87-93. doi: 10.1016/j.bbmt.2012.08.010. Epub 2012 Aug 23.

44.

Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma.

Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN.

Leuk Lymphoma. 2012 Nov;53(11):2159-65. doi: 10.3109/10428194.2012.690605. Epub 2012 May 21.

PMID:
22551474
45.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.

Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN.

Br J Haematol. 2012 May;157(3):321-30. doi: 10.1111/j.1365-2141.2012.09067.x. Epub 2012 Feb 24.

PMID:
22360654
46.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.

Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN.

Haematologica. 2012 Feb;97(2):262-9. doi: 10.3324/haematol.2011.050138. Epub 2011 Oct 11.

47.

The dynamic human immune response to cancer: it might just be rocket science.

Holtan SG, Dronca RS, Nevala WK, Porrata LF, Mansfield AS, Block MS, Leontovich AA, Grotz TE, Turner JD, Frisch HP, Markovic SN.

Immunotherapy. 2011 Sep;3(9):1021-4. doi: 10.2217/imt.11.109. No abstract available.

48.

Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.

Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand RA, Litzow MR, Hogan WJ, Porrata LF, Holtan SG.

Biol Blood Marrow Transplant. 2012 Apr;18(4):600-7. doi: 10.1016/j.bbmt.2011.08.007. Epub 2011 Aug 16.

49.

Relapsed hepatosplenic T-cell lymphoma heralded by a solitary skin nodule.

Hocker TL, Wada DA, McPhail ED, Porrata LF, el-Azhary RA, Gibson LE.

J Cutan Pathol. 2011 Nov;38(11):899-904. doi: 10.1111/j.1600-0560.2011.01741.x. Epub 2011 Jul 14.

PMID:
21752051
50.

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH.

Blood. 2011 Nov 3;118(18):4882-9. doi: 10.1182/blood-2011-02-334904. Epub 2011 Jul 1.

Supplemental Content

Loading ...
Support Center